Loading data for BLLN — first visit, this takes a few seconds.
BillionToOne, Inc.
100.82 +2.05 (2.08%)
100.88 +0.06%
- Ринкова капіталізація
- $4.76B
- Обсяг торгів
- 420K
- Наступна дата звітності
- Nov 5, 2026
BillionToOne, Inc. (BLLN): ціна акції, аналіз і дані
Внутрішня вартість
Прогноз аналітиків
Прогнози по акціях →Останні результати
| Факт | До прогнозу | Зміна р/р | |
|---|---|---|---|
| Виручка | $109.4M | n/a | +64.40% |
| EPS | $0,36 | +$0,20 | n/a |
Показники
- Купівля
- 72.31
- Ринкова капіталізація
- 4.76B
- Виручка (ttm)
- 397M
- Чистий прибуток (ttm)
- 33.2M
- n/a
- 0.71
- 142
- 67.89
- P/B (ttm)
- 8.79
- P/S (ttm)
- 11.97
- Дата звіту
- Nov 5, 2026
- Продаж
- 125.37
- Обсяг торгів
- 420,311
- Сер. обсяг (20 дн.)
- 718,320
- Відкриття
- 98.00
- Попереднє закриття
- 98.77
- Діапазон дня
- 98.00 - 101.98
- Діапазон за 52 тижні
- 61.96 - 150.44
- Аналітик
- n/a
- Цільова ціна
- n/a
- Дивіденди
- n/a
- Екс-дивідендна дата
- n/a
Про BillionToOne, Inc.
Профіль →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
Галузь Diagnostics & Research
Сектор Healthcare
Дата IPO Nov 6, 2025
Працівники 713
Біржа NasdaqGS
Тікер BLLN